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Abstract 
The orchestrated homeostatic action of autophagy and exosome biogenesis provides a 
potential causal relation with lymphomagenesis. This study aims to characterize the 
differently expressed proteins associated with both above-mentioned pathways, as 
well as to explore their potential implication in therapeutic response controlling 
lymphomagenesis via N3a-induced re-activated p53 in different lymphoma subtypes. 
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Abbreviations: 
N3a:  Nutlin-3a  
wt p53: wild-type p53 
MDM2: Μurine double minute 2  
HL:  Hodgkin lymphoma   
MCL:  Mantle cell lymphoma   
ALCL:  Anaplastic large cell lymphoma  
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Lymphoma consists of a group of B- 
and T- cell haematologic malignancies 
with increasing incidence rates that, 
unlike most cancers, commonly harbor 
a functionally inactivated wild-type 
(wt) p53. This feature promotes the 
rationale strategy for a p53-restoration 
lymphoma treatment as a promising 
therapeutic strategy. Accumulating 
data demonstrate that the non-
genotoxic re-activation of wt p53 using 
Nutlin-3a (N3a) in lymphomas has a 
promising potential compromising 
their progression. N3a is a small 
molecule, antagonist of p53’s 
physiological negative regulator, 
MDM2 (murine double minute 2), that 
occupies the p53-binding site of 
MDM2, disrupting the p53-MDM2 
interaction (Vassilev, 2004). More 
specifically, several in vitro and in vivo 
studies demonstrate that N3a promotes 
cell cycle arrest and apoptosis (Drakos 
et al., 2007; Drakos, Atsaves, Li, et al., 
2009; Drakos, Atsaves, Schlette, et al., 
2009), while autophagy activity is 
shown to be cell type-dependent and 
context-dependent (Zhang, 2018). 
Autophagy is a highly conserved 
intracellular pathway that takes place 
at basal levels in normal cells, allowing 
defective protein and organelle 
degradation. In lymphomas, autophagy 
acts as a two-edged sword, working 
either in a cytoprotective manner or 
promoting growth arrest and/or cell 
death, depending on the circumstances 
(Zhang, 2018). Interestingly, 
autophagy regulators have been shown 
to modulate exosome release, while the 
cellular metabolic state has been 
suggested to fine tune the balance 
between exosome release and 
autophagy (Baixauli and Carlos Lσpez-
Otνn and Maria Mittelbrunn, 2014). 
The cell-derived exosomes serve as a 
cell-to-cell communication system that 
delivers molecular and genetic signals 
to close or remote cells reprograming 
their functions (Boyiadzis and 
Whiteside, 2017). The release of these 
extracellular nanovesicles, recently 
implicated in the spread of harmful 
proteins and in cross-talks with cancer-
related pathways, has been shown to 
modulate lymphoma cell susceptibility 
to antibody therapy (Aung et al., 
2011). The coordinated action of 
autophagy and exosome biogenesis, 
regulation and secretion play an 
essential role in preserving cellular 
fitness. The secretion of exosomes may 
operate in close cooperation with the 
autophagic pathway to maintain 
protein and RNA homeostasis, and to 
aid the propagation of neighboring-cell 
signaling process, in order to 
orchestrate systemic responses at the 
organismal level (Baixauli and Carlos 
Lσpez-Otνn and Maria Mittelbrunn, 
2014), thus providing a potential 
causal relation with lymphomagenesis.  
Recent advances in the field of mass 
spectrometry (MS)-based proteomics 
coupled with progress in proteomics 
experimental and bioinformatics 
pipelines, have allowed the hypothesis-
free study of specific processes of 
interest in detail. To this end, MS-
based quantitative proteomics holds 
incremental value in deciphering the 
heterogenous and complex deregulated 
molecular mechanisms and deregulated 
pathways in human lymphoma (Psatha 
et al., 2017). Therefore, the 
investigation of the autophagy and 
exosomal proteomic profile in wt p53 
lymphomas may facilitate the 
decryption of how the secretion of 
exosome-content is linked to the 
autophagy pathway, shedding light in 
the field of lymphoma biopathology.  
In this perspective report, we discuss 
such a study that aims to detect the 
differentially expressed proteins 
associated with autophagy and 
exosomal pathways, to evaluate their 
functional relationship, and explore 
their potential implication in 
therapeutic response controlling  
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Figure 1: Topological protein interaction network of autophagy, mitophagy and exosomes 
proteins in (Hodgkin lymphoma (HL), mantle cell lymphoma (MCL) and anaplastic large cell 
lymphoma (ALCL). All the autophagy, mitophagy and exosomes proteins identified in HL, 
MCL and ALCL were mapped on a topological protein interaction map, indicating the known 
or predicted interaction, as well as their cellular topology. The colors indicate the protein 
identification and their relative abundance in the different lymphoma cell-types after N3a-
treatment. As it is shown in the inset box, white is the lowest abundance where dark blue is 
the highest. Grey indicates no identification of the specific protein in the given lymphoma 
type. 
 
lymphomagenesis using N3a to re-
activate p53 in different lymphoma 
subtypes.  
Initially, in vitro human lymphoma cell 
lines that were used as model system 
of three different lymphoma subtypes 
(Hodgkin lymphoma (HL), mantle cell 
lymphoma (MCL) and anaplastic large 
cell lymphoma (ALCL)), were 
screened for the antiproliferative effect 
of N3a related to p53’s restoration, 
exhibiting enhanced apoptotic death. 
Next, total proteome corresponding to 
the three lymphoma subtypes before 
and after N3a-treatment was subjected 
to comparative proteomic analyses, 
and selected proteins were confirmed 
by immunoblotting.  
Global proteomic analysis detected 
more than 4000 proteins, while 
functional pathway analysis revealed 
more than 32 proteins to be related to 
autophagy (including mitophagy) and 
77 to be related to exosomal pathways. 
N3a induced autophagic stimulation in 
HL, MCL, ALCL, in a different, cell-
type-dependent manner, involving 
increased levels of well-known p53 
targets, such as DRAM and PRKAB1. 
DRAM, a p53-mediated modulator of 
autophagy, holds a critical role for 
programmed cell death, linking 
autophagy to p53 signaling pathway 
and apoptosis (Crighton et al., 2006). 
The identified PRKAB1 is the beta 
subunit of AMP-activated protein 
kinase (AMPKb), a central energy 
sensor. AMPK activates 
serine/threonine kinase ULK1, playing 
a key role in autophagy promotion 
(Lee et al., 2010). Moreover, treatment 
with N3a was associated, among other 
proteins, with the deregulation of 
several Rab GTPases, known to play a 
direct and significant role in the 
endocytic and exosome secretion 
pathways, such as Rab3, Rab13 and 
Rab27 (Blanc and Vidal, 2018). 
Generally, the resulting data indicate 
that endosome-lysosome fusion is 
possibly increased in all lymphoma 
cell lines after treatment, as well as 
exosome secretion. Vesicle fusion is 
suggested to be higher in ALCL and 
HL cell line, whose trafficking may be 
regulated by Rab13. In addition, 
protein interaction analysis revealed 
the degree of functional correlation and 
interconnections among exosomes- and 
autophagy-related proteins and their 
topology, suggesting potential 
targeting markers against lymphoma 
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development (Figure 1).  
Our hypothesis-free approach seeks to 
investigate the influence autophagy 
and exosomes biogenesis and secretion 
have in the context of human 
lymphomas, and lymphomas that are 
more tolerant to therapeutic 
approaches, using the nongenotoxic 
restoration of p53 as a therapeutic 
strategy. Overall, the resulting data 
indicate that N3a is a potent agent that 
induces significant lymphoma cell 
death and promotes autophagy. 
Autophagy induction may increase the 
secretion and the intercellular 
spreading of selected proteins in 
exosomes that contribute to the 
advance of the lymphoma neoplastic 
transformation. This is another 
example of the many different escape 
mechanisms lymphomas evolve to 
avoid host anti-lymphoma 
surveillance, leaving several questions 
for further investigation.  
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